Establishment Labs Holdings (ESTA) Announces Preliminary Results for Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Establishment Labs Announces Preliminary Results for Fourth Quarter and Full Year 2019; Reports Record Revenue
January 28, 2020 4:06 PM ESTNEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on Womens Health initially in the breast aesthetics and reconstruction market today announced preliminary financial results for the fourth quarter and full year 2019, with total revenue growth for the quarter of 43% to 49%.
2019 was another extraordinary year for Establishment Labs, and we ended the year on a strong note with our sixth consecutive quarter of record revenue performance, said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. We achieved increased... More
Establishment Labs Announces Proposed Public Offering of Common Shares
January 28, 2020 4:02 PM ESTNEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the Company), a medical technology company focused on Womens Health initially in the breast aesthetics and reconstruction market today announced that it has commenced a public offering of approximately $55,000,000 of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to $8,250,000 of additional common shares. The offering is subject to market conditions, and there can be no assurance as to whether or when the... More
